Sickle cell disease is a group of genetic hemoglobin disorders. All over the world, about 300,000 children with these disorders are born each year. Acute sickle cell pain episodes are the most common cause of hospitalization. Pregnancy in women with sickle cell disease is associated with an increased incidence of maternal and fetal morbidity and mortality. Pregnancy is not contraindicated for women with SCD. However, prenatal care for women with SCD should be managed by a multidisciplinary team that includes an obstetrician, nutritionist, primary care physician, and hematologist. The pregnancies are at higher risk of unceremonious abortion, premature labor, pseudo-toxemia and cesarean section. During pregnancy, the disease may become more acute and pain occurrences may happen more frequently. Since any of the complications of sickle cell disease may occur during pregnancy, the mother should be followed in a setting where more than routine obstetrical care is available. This is usually best achieved by continued follow-up by a sickle cell knowledgeable provider as well as attendance at a “high risk” obstetrical clinic.

It is generally found that the increased fetal loss in mothers with sickle cell disease, it attributed to increased incidence of abortion , intrauterine growth retardution, perinatal and infant death, published reports indicated a previous abortion rate of 50% in (SS) disease. However with imporoved maternal and fetal care, perinatal death has been reduced to 12.2% (hemoglobin SS).In a previous studies in Iran, sickle cell was shown that to be relativly milder in clinical manifestations. Those findings have been attributed to presence of a high percentage high percentage of FHb. We reported here 5 cases of (SS) and sickle - Beta thalassemic pregnant women with relativly high percentage of FHb and history of previous abortions, They complate the last pregnancy in Ahwaz Thalassemic Center and deliverd mature newborn through normal delivery or C/S at the 36-37 weeks of gestation. They did not have any clinical problams such as toximia - pregnacy, hypertesion, proteinuria or interautrine growth retardation.They treated by periodic regular prohylactic packed red cell transfusion during pregnancy if Hb became less than 8-9gr% or less 30% from normal baseline

It is generally found that the increased fetal loss in mothers with sickle cell disease, it attributed to increased incidence of abortion , intrauterine growth retardution, perinatal and infant death, published reports indicated a previous abortion rate of 50% in (SS) disease. However with imporoved maternal and fetal care, perinatal death has been reduced to 12.2% (hemoglobin SS).In a previous studies in Iran, sickle cell was shown that to be relativly milder in clinical manifestations. Those findings have been attributed to presence of a high percentage high percentage of FHb. We reported here 5 cases of (SS) and sickle - Beta thalassemic pregnant women with relativly high percentage of FHb and history of previous abortions, They complate the last pregnancy in Ahwaz Thalassemic Center and deliverd mature newborn through normal delivery or C/S at the 36-37 weeks of gestation. They did not have any clinical problams such as toximia - pregnacy, hypertesion, proteinuria or interautrine growth retardation.They treated by periodic regular prohylactic packed red cell transfusion during pregnancy if Hb became less than 8-9gr% or less 30% from normal baseline

Context: The COVID-19 pandemic emerged in China and spread to the majority of countries worldwide, causing numerous health problems and restrictions on the people’ s lifestyles. The complications of this disease can be much more severe in patients who have a weakened immune system or a chronic disease. Sickle cell disease is a genetic disorder in which the immune system is impaired. Exposure to COVID-19 will have severe consequences in the sickle cell disease patients. In this study aimed to investigate the relationship between this disease with the COVID-19 pandemic. Evidence Acquisition: Embase, Scopus, Pub Med databases were reviewed. Keywords were combined as (“ COVID19” OR “ Coronavirus” AND “ Anemia sickle Cell” OR “ Sickle cell disease” ). The results of related articles were used. Results: At the time of the COVID-19 pandemic, chronic patients and those with weakenedimmunesystems need to be more socially inclined to be less exposed to the COVID-19 virus. Conclusions: When producing the COVID vaccine, high-risk groups such as sickle cell anemia patients should be given priority.

A genetic mutation in the beta-globin gene causes the common illness known as Sickle Cell Disease (SCD). "Sickle Cell Disease (SCD) is caused by a genetic mutation in the beta-globin gene, leading to the synthesis of hemoglobin S." The mutation can manifest in either homozygous or heterozygous form, potentially in combination with another mutation in the hemoglobin gene. Various approaches were created to accurately identify Sickle Cell Disease with high sensitivity and specificity. The present study aimed to determine the frequency of various genotypes of Sickle Cell Disease (SCD) in Kurdistan, Iraq, using hematological testing, hemoglobin isolation, and genetic testing. One hundred patients were examined individually. The Duhok-Jin center in Kurdistan, Iraq, provided the data in 2019 and 2020. The analysis was conducted in 2020. The procedures used for screening include a complete blood count, while confirmatory tests involve hemoglobin separation and genetic tests. The cohort of 100 participants in the study had a mean age of 15.8. 61% of the patients were diagnosed with sickle cell anemia, whereas the remaining 39% were identified with S/β-thalassemia. "In individuals with sickle cell anemia, the concentrations of HbS, HbF, and HbA2 were measured as 65.0 ± 15.04, 19.52 ± 17.3, and 2.65 ± 0.8, respectively. In individuals with S/β-thalassemia, the concentrations were 63.03 ± 13.44, 19.95 ± 12.0, and 4.63 ± 0.9, respectively." This investigation demonstrates that combining hematologic tests and HPLC with a confirmatory test, such as DNA analysis, can lead to an accurate diagnosis of Sickle Cell Disease.